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Role of CD8+ regulatory T cells in organ 
transplantation
Introduction
Organ transplantation is the preferred treatment of choice for 
patients with end-stage organ failure. However, the mortality 
and mobility associated with broad immunosuppression 
in transplant patients remains a significant barrier to the 
actual therapeutic potential of  organ transplantation. The 
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recent emergence of  composite tissue transplantation, 
which is the treatment of  choice for patients suffering 
from severe burns and trauma, presents new challenges 
and opportunities for long-term transplant survival without 
drug-associated toxicities. Induction of  immune tolerance 
is essential for avoiding pathogenic immune responses to 
self-antigens and alloantigens. Tolerance is also an ideal 
method of  weaning patients off  immunosuppressive 
drugs. It has been well-established that regulatory T cells 
(Tregs) are critical for maintaining immune tolerance by 
suppressing both autoimmunity and alloimmunity. There 
are multiple cell types in the immune system that exhibit 
immunosuppressive properties. In addition to the much 
publicized CD4+CD25+Foxp3+ Tregs, CD8+ Tregs have 
emerged as another key player in immune regulation. 
A B S T R A C T
CD8+ T cells are regulatory T cells (Tregs) that suppress both alloimmunity and autoimmunity in many animal models. This class 
of regulatory cells includes the CD8+CD28-, CD8+CD103+, CD8+FoxP3+ and CD8+CD122+ subsets. The mechanisms of action of these 
regulatory cells are not fully understood; however, the secretion of immunosuppressive cytokines, such as interleukin (IL)-4, IL-10 
and transforming growth factor beta (TGF-β) as well as the direct killing of target cells via Fas L/Fas and the perforin/granzyme 
B pathways have been demonstrated in various models. Further studies are necessary to fully understand the mechanisms 
underlying the suppressive eﬀ ects of Tregs and to provide experimental support for potential clinical trials. We recently observed 
that CD8+CD122+ Tregs more potently suppressed allograft rejection compared to their CD4+CD25+ counterparts, supporting the 
hypothesis that CD8+ Tregs may represent a new and promising Treg family that can be targeted to prevent allograft rejection 
in the clinic. In this review, we summarize the progress in the fi eld during the past 7-10 years and discuss CD8+ Treg phenotypes, 
mechanisms of action, and their potential clinical applications; particularly in composite tissue transplants in burn and trauma 
patients.
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Early studies showed that CD8+ T cells could suppress 
immune responses, thereby functioning as suppressor 
cells,[1,2] and tremendous progress has occurred regarding 
their suppression of  alloimmunity and mechanisms 
of  action. For example, Liu et al., demonstrated that 
CD8+CD28- T cells inhibited T helper alloreactivity in an 
major histocompatibility complex (MHC) class I-restricted 
manner.[3] These CD8+ Tregs also induced xenoreactive 
CD4+ T-cell anergy.[4] Human CD8+ Tregs inhibited 
graft-versus-host disease (GVHD) in humanized mice.[5] 
Additionally, either donor-specific or induced CD8+FoxP3+ 
Tregs facilitated skin allograft survival in certain models.[6] 
Moreover, antigen-induced CD8+CD103+ Tregs have been 
shown to suppress alloreactive effector T cell function.[7] 
More importantly, several recent studies have shown that 
CD8+CD122+ T cells are also potent Tregs that inhibit 
both alloimmunity and autoimmunity.[8-19] In particular, 
we have recently found that in an islet transplant model, 
naturally occurring CD8+CD122+ Tregs in the periphery 
more potently suppressed allograft rejection than their 
CD4+CD25+ counterparts.[20] Therefore, CD8+ Tregs may 
represent a new and promising Treg family that can be 
targeted to treat autoimmune diseases and allograft rejection 
in the clinic. Here, we review the most recent progress in 
the field and discuss potential clinical applications for the 
induction of  tolerance to composite tissue transplants.
CD8+CD28− Tregs
Previous studies have demonstrated that CD8+CD28- T cells 
are immunosuppressive.[18] Liu et al., originally reported 
the specific suppression of  T helper alloreactivity by 
MHC class-I-restricted CD8+CD28- T cells,[3] which were 
generated by multiple rounds of  in vitro allostimulation 
of  peripheral blood mononucleocytes. These MHC class-
I-restricted CD8+CD28- T cells induced xenoreactive 
human CD4+ T-cell anergy upon specific recognition of  
MHC class-I antigens.[4] Adoptive transfer of  CD8+CD28- 
cells resulted in profound inhibition of  corneal xenograft 
rejection.[21] Qa-1-restricted CD8+CD28- T cells regulated 
the reactivation of  both T cells and natural killer T (NKT) 
cells.[22] Human xenospecific CD8+CD28- Tregs inhibited T 
helper cell responses to porcine aortic endothelial cells by 
suppressing necrosis factor (NF)-kappa B activity in porcine 
antigen-presenting cells (APCs).[23] Allospecific and induced 
CD8+CD28-FoxP3+ Tregs induced immunoglobulin-like 
transcript (ILT)3+/ILT4+ tolerogenic endothelial cells or 
APCs, down-regulated the expression of  costimulatory 
(CD80/CD86) and adhesion (CD54/CD58) molecules, 
thereby suppressing alloimmune responses.[23-26] Although 
induced CD8+CD28- Tregs expressed FoxP3,[24] natural 
CD8+CD28- Tregs were FoxP3-negative.[27] The induced, but 
not natural, CD8+CD28- Tregs expressed glucocorticoid-
induced tumor necrosis factor receptor-related protein 
(GITR) and cytotoxic T-cell antigen 4 (CTLA4), 
whereas both Tregs expressed CD62L[27,28] [Figure 2]. 
Moreover, graft function was maintained with minimal 
or no immunosuppression in patients that had circulatory 
CD8+CD28- Tregs.[29] The expansion of  CD8+CD28- Tregs 
was associated with the reduced occurrence of  acute or 
chronic rejection.[30] The adoptive transfer of  CD8+CD28- 
Tregs from tolerized liver transplant recipients alleviated 
acute allograft rejection in rats.[31] Donor-specific T cell 
vaccination induced CD4+CD25+ or CD8+CD28- Tregs that 
promoted transplant tolerance in new recipient mice that 
received a cardiac allograft.[32] Taken together, mounting 
evidence suggests that CD8+CD28- cells are Tregs that 
can either suppress allograft rejection or promote allograft 
tolerance. CD8+CD28- Tregs are the primary effectors of  
transplant tolerance and act on the endothelium and antigen 
presenting cells (APCs) to induce a tolerogenic phenotype 
and inhibit CD4+ T helper cell alloreactivity.
CD8+CD103+ Tregs
It has been shown that a CD8+ T cell population lacking 
CD44 but expressing CD103 produced transforming growth 
factor beta (TGF-β), inhibit CD4+ proliferation in vitro, and 
attenuate adoptively transferred ileitis in vivo, most likely 
by counteracting the proinflammatory role of  the CD44high 
subset of  T cells.[33] Therefore, these CD8+ Tregs exhibit a 
naive T cell phenotype (CD8+CD103+CD44lowCD62Lhigh), as 
shown in Figure 1. In contrast, allostimulated CD8+CD103+ 
Tregs displayed limited effector functions, such as 
cytotoxicity and interferon (IFN)-γ production. Instead, 
CD8+CD103+ Tregs suppressed alloreactive effector T 
cells.[7] Lu et al., demonstrated that CD8+CD103- T cells 
differentiated into CD8+CD103+FoxP3+ T cells after in vitro 
stimulation with either alloantigens or transforming growth 
factor (TGF)-β and that the number of  CD8+CD103+ 
Tregs increased in spontaneously tolerant recipients of  a 
liver allograft.[34] Rapamycin not only promoted the in vitro 
generation of  CD8+CD103+ Tregs after allostimulation, 
but also enhanced their suppressive capacity.[35] However, a 
study by Feng et al., found that CD103 expression by CD8+ 
T cells was required for the destruction of  islet allografts 
because CD8+CD103- T cells failed to infiltrate the islet 
grafts,[36] indicating that CD103 may be an effector but 
not a regulatory molecule. Therefore, further studies are 
necessary to better define the role of  CD103 in alloreactive 
CD8+ T cell functions.
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CD8+CD122+ Tregs
Recent studies have shown that naturally occurring 
CD8+CD122+ T cells control T cell homeostasis and play an 
important role in the suppression of  autoimmune diseases.[8] 
The transfer of  CD8+CD122+ Tregs significantly improved 
the clinical symptoms of  experimental autoimmune 
encephalomyelitis (EAE), indicating a role for CD8+CD122+ 
Tregs in the recovery phase of EAE.[37] Brain DCs expressing 
the B7-H1 molecule recruit CD8+CD122+ Tregs to the 
inflammatory site, which causes a decrease in the clinical 
EAE peak values.[38] Notably, CD8+CD38+CD122+ Tregs 
inhibited effector CD4+ T cell proliferation in an antigen-
nonspecific manner and reduced the clinical score of  
murine EAE as well as delayed disease occurrence.[39] A 
recent study showed that CD8+CD122+ T cells also played 
a regulatory role in EAE models of  HLA-DR3 transgenic 
mice; whereas, CD8+CD122- T cells had an opposite 
role.[16] Furthermore, CD8+CD122+ Tregs suppressed 
other autoimmune diseases in many animal models. The 
depletion of CD8+CD122+ T cells increased the incidence of  
autoimmune Graves’ hyperthyroidism in a mouse model,[40] 
suggesting that CD8+CD122+ T cells play an essential role 
in the inhibition of  autoimmune hyperthyroidism. B6-Yaa 
mutant mice developed systemic lupus erythematous-like 
disease in association with a defect in CD8+CD122+ Treg 
activity, suggesting that the Treg subset may be utilized 
to treat systemic lupus erythematous-like autoimmune 
disease.[15] Therefore, in multiple experimental animal 
models, CD8+CD122+ Tregs play an important role in the 
suppression of  various autoimmune diseases.
Recent studies have also demonstrated that CD8+CD122+ 
Tregs play a role in suppressing alloimmune responses. We 
originally reported that CD8+CD122+ Tregs suppressed 
murine allograft rejection.[17] We also found that the PD-1+ 
component of  these Tregs were more effective than the 
unfractionated CD8+CD122+ Treg population;[17] whereas, 
antigen-specific CD8+CD122+PD-1- cells were memory T 
cells that could respond to a previously encountered antigen 
quickly and efficiently. Furthermore, we demonstrated 
that CD8+CD122+ Tregs were more potent in suppressing 
allograft rejection than their CD4+CD25+ counterparts,[20] 
suggesting that CD8+CD122+ Tregs may be a better target 
for the treatment of  allograft rejection. In summary, 
CD8+CD122+ Tregs regulate both autoimmunity and 
alloimmunity and may participate in immune regulation 
in vivo for various diseases.
CD8+CD122+ Tregs and the classical CD4+CD25+ Tregs both 
express the interleukin (IL)-2 receptor. Specifically, CD122 
is the β subunit of  the IL-2 receptor on T cells; whereas, 
Figure 1: CD8+ regulatory T cell (Treg) phenotypes. Natural CD8+CD122+ Tregs are CD44highCD62L+CD127+ and partially PD-1-positive (PD-1+/-) 
but are FoxP3-negative. Natural CD8+CD28- Tregs (nTreg) are CD44lowCD62L+ but GITR-CTLA4-FoxP3-; whereas, induced CD8+CD28- Tregs 
(iTreg) are CD44highCD62L+, but GITR+CTLA4+FoxP3+. CD8+CD103+ Tregs are CD44lowCD62LhighFoxP3+. GITR = Glucocorticoid-induced tumor 
necrosis factor receptor-related protein, CTLA4 = cytotoxic T-cell antigen 4.
Figure 2: Mechanisms underlying CD8+ Treg suppression. Mechanisms 
responsible for CD8+ Treg suppression include immunosuppressive 
cytokines and the killing of target T cells via the perforin/granzyme B 
and Fas L/Fas pathways as well as the downregulation of CD80/CD86 
but the upregulation of immunoglobulin-like transcript 3/4 (ILT3/4) that, 
in turn, promotes CD8+ Treg expansion antigen presenting cell (APC).
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CD25 is the α subunit of  the IL-2 receptor.[41] To identify 
more effective Tregs for potential clinical applications, we 
evaluated the efficacy of  naturally arising CD8+CD122+ vs 
CD4+CD25+ Tregs for suppressive activities. Surprisingly, 
we found that CD8+CD122+ Tregs were much more 
efficient in the suppression of  allograft rejection and 
underwent faster homeostatic proliferation than their 
CD4+CD25+ counterparts.[20] In addition, CD8+CD122+ 
Tregs produced significantly more IL-10 and were more 
effective in the suppression of  in vitro T cell proliferation 
than their CD4+CD25+ counterparts. Importantly, adoptive 
transfer of  CD8+CD122+ Tregs but not CD4+CD25+ 
Tregs, together with the infusion of  recombinant IL-15, 
significantly delayed allograft rejection in normal wild-
type mice. In contrast, the transfer of  CD4+CD25+ 
Tregs with the administration of  either recombinant 
IL-2 or IL-15 did not significantly prolong islet allograft 
survival.[20] We hypothesized that IL-2 administration 
promoted the expansion of  both CD4+CD25+ Tregs and 
conventional effector T cells, which did not alter the overall 
immune balance; whereas, the administration of  IL-15 
enhanced the expansion and function of  CD8+CD122+ 
but not CD4+CD25+ Tregs. Therefore, naturally occurring 
CD8+CD122+ Tregs appear to be a more promising target 
for suppressing allograft rejection than their CD4+CD25+ 
counterparts. Further studies are warranted to improve 
CD8+CD122+ Treg therapies and provide additional 
experimental data for clinical trials.
Mechanisms of action
The mechanisms underlying CD8+ Treg suppression are 
not fully understood. However, multiple mechanisms are 
likely to be involved, including the killing or direct lysis of  
target cells, the induction of  CD4+ T cell anergy, and the 
secretion of  immunosuppressive cytokines and molecules. 
Different subsets of  CD8+ Tregs may utilize distinct 
mechanisms. Studies by Cantor’s group have demonstrated 
that perforin-mediated cytotoxicity is required for the 
suppressive activity of  Qa-1-restricted CD8+ Tregs;[42] 
whereas, others have shown that CD11c+CD8+ Tregs 
can directly kill activated CD4+ T cells through the Fas 
ligand-Fas death pathway[43] [Figure 2]. CD8+CD28- Tregs 
induced xenoreactive human CD4+ T-cell anergy[4] and also 
downregulated expression of  the costimulatory molecules 
CD80/CD86 on APCs,[23] which indirectly block T cell 
priming by APCs. TGF-β expanded CD8+CD103+ Tregs 
displayed cytotoxicity towards allospecific effector T cells 
through cell-to-cell contact.[7] Zheng et al., demonstrated 
that alloantigen-specific suppression by human CD8+ 
Tregs was partially dependent on IL-10, TGF-β, GITR 
and CTLA-4 expression.[44] CD8+CD28- Tregs induced 
ILT3+/ILT4+ expression on endothelial cells or APCs 
and downregulated costimulatory (CD80/CD86) and 
adhesion (CD54/CD58) molecules, resulting in reduced 
alloreactivity.[23-26] The increased ILT3+/ILT4+ expression, 
in turn, promoted the differentiation of  CD8+CD28-
FoxP3+ Tregs,[24] reinforcing their suppressive capacity. 
Moreover, ILT3 directly induced CD4+ Th cell anergy 
and suppressed the differentiation of  IFN-γ-producing 
effector CD8+ CTL.[45]
The mechanisms of  action for CD8+CD122+ Treg 
suppression are also not well-defined. As shown in Figure 
2, IL-10 produced by CD8+CD122+ Tregs appears to be 
a primary mechanism responsible for suppression.[9,17,46] 
Endharti et al., presented the first data showing that 
CD8+CD122+ Tregs suppressed IFN-γ production and 
the proliferation of  CD8+ T cells by producing IL-10 in 
vitro. [9] CD8+ Tregs also recognized activated T cells via 
the interaction of  the MHC class I-αβ TCR and regulated 
target T cells by producing IL-10.[46] We also observed that 
the suppression of  allograft rejection by IL-10-deficient 
CD8+CD122+ Tregs was largely diminished.[17] Activated 
CD8+CD122+ Tregs from RasGRP1(-/-) mice synthesized 
IL-10 and inhibited the proliferation of  CD8+CD122- T 
cells.[10] However, IL-10 did not account for all mechanisms 
underlying CD8+CD122+ Treg suppression.[17] Other 
mechanisms, in addition to IL-10 production, may be 
involved in CD8+CD122+ Treg suppression. In particular, 
CD8+CD122+ Tregs also released IFN-γ and TGF-β that 
suppressed CD4+ T cell activation.[16] It remains to be 
determined whether the perforin/granzyme B pathway is 
also involved in regulating effector T cells by CD8+CD122+ 
Tregs. Despite these findings, further studies are required 
to fully identify the mechanisms responsible for the 
suppression of  alloimmunity or autoimmunity.
Conclusion
Many recent studies have shown that the CD8+ component 
of  T cells can also serve as Tregs in vitro and in vivo, 
although relatively little is known about these cells 
compared to the conventional CD4+CD25+ Tregs. 
CD8+ cells suppress both alloimmune responses and 
autoimmunity in many animal models. Multiple subsets 
of  CD8+ Tregs have been identified thus far, including 
the CD8+CD28-, CD8+CD103+, CD8+FoxP3+ and 
CD8+CD122+ populations. The mechanisms of  action 
of  these cells are not well understood because of  their 
plasticity and heterogeneity. Further investigation is 
necessary to fully understand the distinct mechanisms 
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underlying their suppression as well as the mechanism 
by which CD8+ Tregs interact with other types of  Tregs 
in the induction and maintenance of  immune tolerance. 
These studies will help lay the groundwork for potential 
clinical trials. Most importantly, our new studies reveal 
that CD8+CD122+ Tregs more potently suppress allograft 
rejection than their CD4+CD25+ counterparts. Therefore, 
CD8+ Tregs likely represent a new and promising Treg 
family that can be targeted to suppress allograft rejection 
or induce long-term allograft survival or tolerance in the 
clinic. This will undoubtedly benefit transplant patients, 
including those with composite tissue transplants because 
of  trauma and burns.
References
1. Gershon RK, Kondo K. Cell interactions in the induction 
of tolerance: The role of thymic lymphocytes. Immunology 
1970;18:723-37.
2. Cantor H, Shen FW, Boyse EA. Separation of helper T 
cells from suppressor T cells expressing different Ly 
components. II. Activation by antigen: After immunization, 
antigen-specific suppressor and helper activities are 
mediated by distinct T-cell subclasses. J Exp Med 
1976;143:1391-40.
3. Liu Z, Tugulea S, Cortesini R, Suciu-Foca N. Specific 
suppression of T helper alloreactivity by allo-MHC class 
I-restricted CD8+CD28- T cells. Int Immunol 1998;10:775-83.
4. Colovai AI, Liu Z, Ciubotariu R, Lederman S, Cortesini 
R, Suciu-Foca N. Induction of xenoreactive CD4+ T-cell 
anergy by suppressor CD8+CD28- T cells. Transplantation 
2000;69:1304-10.
5. Zheng J, Liu Y, Liu M, Xiang Z, Lam KT, Lewis DB, et al. 
Human CD8+ regulatory T cells inhibit GVHD and preserve 
general immunity in humanized mice. Sci Transl Med 
2013;5:168-9.
6. Lerret NM, Houlihan JL, Kheradmand T, Pothoven KL, Zhang 
ZJ, Luo X. Donor-specific CD8+ Foxp3+ T cells protect skin 
allografts and facilitate induction of conventional CD4+ 
Foxp3+ regulatory T cells. Am J Transplant 2012;12:2335-47.
7. Koch SD, Uss E, van Lier RA, ten Berge IJ. Alloantigen-
induced regulatory CD8+CD103+ T cells. Hum Immunol 
2008;69:737-44.
8. Rifa’i M, Kawamoto Y, Nakashima I, Suzuki H. Essential 
roles of CD8+CD122+regulatory T cells in the maintenance 
of T cell homeostasis. J Exp Med 2004;200:1123-34.
9. Endharti AT, Rifa IM, Shi Z, Fukuoka Y, Nakahara Y, 
Kawamoto Y, et al. Cutting edge: CD8+CD122+ regulatory T 
cells produce IL-10 to suppress IFN-gamma production and 
proliferation of CD8+ T cells. J Immunol 2005;175:7093-7.
10. Chen X, Priatel JJ, Chow MT, Teh HS. Preferential 
development of CD4 and CD8 T regulatory cells in RasGRP1-
deficient mice. J Immunol 2008;180:5973-82.
11. Shi Z, Rifa’i M, Lee YH, Shiku H, Isobe K, Suzuki H. 
Importance of CD80/CD86-CD28 interactions in the 
recognition of target cells by CD8+CD122+ regulatory T cells. 
Immunology 2008;124:121-8.
12. Molloy MJ, Zhang W, Usherwood EJ. Suppressive CD8+ 
T cells arise in the absence of CD4 help and compromise 
control of persistent virus. J Immunol 2011;186:6218-26.
13. Endharti AT, Okuno Y, Shi Z, Misawa N, Toyokuni S, Ito M, 
et al. CD8+CD122+ regulatory T cells (Tregs) and CD4+ Tregs 
cooperatively prevent and cure CD4+ cell-induced colitis. J 
Immunol 2011;186:41-52.
14. Wang LX, Li Y, Yang G, Pang PY, Haley D, Walker EB, et al. 
CD122+CD8+ Treg suppress vaccine-induced antitumor 
immune responses in lymphodepleted mice. Eur J Immunol 
2010;40:1375-85.
15. Kim HJ, Wang X, Radfar S, Sproule TJ, Roopenian DC, Cantor 
H. CD8+ T regulatory cells express the Ly49 Class I MHC 
receptor and are defective in autoimmune prone B6-Yaa 
mice. Proc Natl Acad Sci U S A 2011;108:2010-5.
16. Mangalam AK, Luckey D, Giri S, Smart M, Pease LR, Rodriguez 
M, et al. Two discreet subsets of CD8 T cells modulate PLP(91-
110) induced experimental autoimmune encephalomyelitis 
in HLA-DR3 transgenic mice. J Autoimmun 2012;38:344-53.
17. Dai H, Wan N, Zhang S, Moore Y, Wan F, Dai Z. Cutting 
edge: Programmed death-1 defines CD8+CD122+ T 
cells as regulatory versus memory T cells. J Immunol 
2010;185:803-7.
18. Guillonneau C, Picarda E, Anegon I. CD8+ regulatory T cells 
in solid organ transplantation. Curr Opin Organ Transplant 
2010.
19. Suzuki M, Konya C, Goronzy JJ, Weyand CM. Inhibitory 
CD8+ T cells in autoimmune disease. Hum Immunol 
2008;69:781-9.
20. Dai Z, Zhang S, Xie Q, Wu S, Su J, Li S, et al. Natural 
CD8+CD122+ T cells are more potent in suppression of 
allograft rejection than CD4+CD25+ regulatory T cells. Am 
J Transplant 2014;14:39-48.
21. Wang J, Jiang S, Shi H, Lin Y, Wang X. Prolongation of corneal 
xenotransplant survival by T-cell vaccination-induced 
T-regulatory cells. Xenotransplantation 2008;15:164-73.
22. Varthaman A, Khallou-Laschet J, Clement M, Fornasa G, 
Kim HJ, Gaston AT, et al. Control of T cell reactivation 
by regulatory Qa-1-restricted CD8+ T cells. J Immunol 
2010;184:6585-91.
23. Ciubotariu R, Li J, Colovai AI, Platt JL, Cortesini R, Suciu Foca 
Cortesini N. Human xenospecific T suppressor cells inhibit 
T helper cell proliferation to porcine aortic endothelial cells, 
and NF-kappaB activity in porcine APC. Hum Immunol 
2001;62:470-8.
24. Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad 
G, Colombo PC, et al. Alloantigen specific CD8+CD28- 
FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic 
endothelial cells, inhibiting alloreactivity. Int Immunol 
2004;16:1055-68.
25. Ciubotariu R, Colovai AI, Pennesi G, Liu Z, Smith D, 
Berlocco P, et al. Specific suppression of human CD4+ Th 
cell responses to pig MHC antigens by CD8+CD28- regulatory 
T cells. J Immunol 1998;161:5193-202.
26. Choi J, Enis DR, Koh KP, Shiao SL, Pober JS. T lymphocyte-
endothelial cell interactions. Annu Rev Immunol 
2004;22:683-709.
27. Scotto L, Naiyer AJ, Galluzzo S, Rossi P, Manavalan JS, 
Kim-Schulze S, et al. Overlap between molecular markers 
expressed by naturally occurring CD4+CD25+ regulatory T 
cells and antigen specific CD4+CD25+ and CD8+CD28- T 
suppressor cells. Hum Immunol 2004;65:1297-306.
28. Yu Y, Zitzner JR, Houlihan J, Herrera N, Xu L, Miller J, et al. 
Common gamma chain cytokines promote rapid in vitro 
expansion of allo-specific human CD8+ suppressor T cells. 
PLoS One 2011;6:e28948.
Su, et al.: CD8+ Treg and transplant survival
Burns & Trauma • January 2014 • Vol 2 • Issue 1 23
29. Sindhi R, Manavalan JS, Magill A, Suciu-Foca N, Zeevi A. 
Reduced immunosuppression in pediatric liver-intestine 
transplant recipients with CD8+CD28- T-suppressor cells. 
Hum Immunol 2005;66:252-7.
30. Lin YX, Yan LN, Li B, Wang LL, Wen TF, Zeng Y, et al. A 
significant expansion of CD8+ CD28- T-suppressor cells 
in adult-to-adult living donor liver transplant recipients. 
Transplant Proc 2009;41:4229-31.
31. Liu Y, Chen N, Chen G, You P. The protective effect of 
CD8+CD28- T suppressor cells on the acute rejection 
responses in rat liver transplantation. Transplant Proc 
2007;39:3396-403.
32. Wang J, Zhang L, Tang J, Jiang S, Wang X. Adoptive transfer 
of transplantation tolerance mediated by CD4+CD25+ and 
CD8+CD28- regulatory T cells induced by anti-donor-specific 
T-cell vaccination. Transplant Proc 2008;40:1612-7.
33. Ho J, Kurtz CC, Naganuma M, Ernst PB, Cominelli 
F, Rivera-Nieves J. A CD8+/CD103 high T cell subset 
regulates TNF-mediated chronic murine ileitis. J Immunol 
2008;180:2573-80.
34. Lu L, Yu Y, Li G, Pu L, Zhang F, Zheng S, et al. CD8 (+) 
CD103 (+) regulatory T cells in spontaneous tolerance of 
liver allografts. Int Immunopharmacol 2009;9:546-8.
35. Uss E, Yong SL, Hooibrink B, van Lier RA, ten Berge 
IJ. Rapamycin enhances the number of alloantigen-
induced human CD103+CD8+ regulatory T cells in vitro. 
Transplantation 2007;83:1098-106.
36. Feng Y, Wang D, Yuan R, Parker CM, Farber DL, Hadley 
GA. CD103 expression is required for destruction of 
pancreatic islet allografts by CD8 (+) T cells. J Exp Med 
2002;196:877-86.
37. Lee YH, Ishida Y, Rifa’i M, Shi Z, Isobe K, Suzuki H. Essential 
role of CD8+CD122+ regulatory T cells in the recovery from 
experimental autoimmune encephalomyelitis. J Immunol 
2008;180:825-32.
38. Zozulya AL, Ortler S, Fabry Z, Sandor M, Wiendl H. The 
level of B7 homologue 1 expression on brain DC is decisive 
for CD8 Treg cell recruitment into the CNS during EAE. Eur 
J Immunol 2009;39:1536-43.
39. Bahri R, Bollinger A, Bollinger T, Orinska Z, Bulfone-Paus 
S. Ectonucleotidase CD38 demarcates regulatory, memory-
like CD8+ T cells with IFN-gamma-mediated suppressor 
activities. PLoS One 2012;7:e45234.
40. Saitoh O, Abiru N, Nakahara M, Nagayama Y. CD8+CD122+ 
T cells, a newly identified regulatory T subset, negatively 
regulate Graves’ hyperthyroidism in a murine model. 
Endocrinology 2007;148:6040-6.
41. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. 
Immunological self-tolerance maintained by activated T cells 
expressing IL-2 receptor alpha-chains (CD25)-breakdown 
of a single mechanism of self-tolerance causes various 
autoimmune diseases. J Immunol 1995;155:1151-64.
42. Lu L, Cantor H. Generation and regulation of CD8(+) 
regulatory T cells. Cell Mol Immunol 2008;5:401-6.
43. Chen Z, Han Y, Gu Y, Liu Y, Jiang Z, Zhang M, et al. CD11c 
(high) CD8+ regulatory T cell feedback inhibits CD4 T cell 
immune response via Fas ligand-Fas pathway. J Immunol 
2013;190:6145-54.
44. Zheng J, Liu Y, Qin G, Chan PL, Mao H, Lam KT, et al. 
Efficient induction and expansion of human alloantigen-
specific CD8 regulatory T cells from naive precursors by 
CD40-activated B cells. J Immunol 2009;183:3742-50.
45. Vlad G, Cortesini R, Suciu-Foca N. CD8+ T suppressor cells 
and the ILT3 master switch. Hum Immunol 2008;69:681-6.
46. Rifa’i M, Shi Z, Zhang SY, Lee YH, Shiku H, Isobe K, et al. 
CD8+CD122+ regulatory T cells recognize activated T cells 
via conventional MHC class I-alphabetaTCR interaction and 
become IL-10-producing active regulatory cells. Int Immunol 
2008;20:937-47.
How to cite this article: Su J, Xie Q, Xu Y, Li XC, Dai Z. Role of CD8+ 
regulatory T cells in organ transplantation. Burn Trauma 2014;2:18-23.
Source of Support: Nil, Confl ict of Interest: None declared.
